University of Pennsylvania researchers nab grant for CAR-T prostate cancer test
The University of Pennsylvania, which has helped pioneer cell therapy approaches to blood cancers, has nabbed an ACGT grant to help battle solid tumors.
The University of Pennsylvania, which has helped pioneer cell therapy approaches to blood cancers, has nabbed an ACGT grant to help battle solid tumors.
Johnson & Johnson has been ordered to pay $344 million in a landmark state court judgment over deceptive marketing practices for its pelvic mesh products.
The Biotechnology Innovation Organization (BIO) has been plugging away at improving diversity in its member companies for years, setting up and ratifying a group of diversity goals in June 2017. Now, the industry group has published its first “state of the industry” report and the results are encouraging—somewhat.
GeNeuro has sold stock at a knock-down price to fund a multiple sclerosis trial. The €17.5 million ($19.3 million) private placement averts a cash crunch and sets GeNeuro up to test temelimab in MS patients whose disability progresses without relapses.
Sanofi’s olipudase alfa has improved outcomes in patients with a rare genetic disease. The primary endpoint success in a phase 2/3 trial, coupled with midphase pediatric results, sets Sanofi up to file for approval in acid sphingomyelinase deficiency (ASMD) next year.
Another ex-Shire executive is jumping the Takeda ship. Melanie Ivarsson, Ph.D., who led clinical programs at Shire before overseeing global clinical operations at Takeda, is now chief development officer at Moderna.
Microsoft announced a new five-year, $40 million artificial-intelligence initiative geared toward global health challenges and research.
Mammoth Biosciences has banked a $45 million second funding round as it looks to double down on its next-gen gene-editing tech.
After its Novartis-partnered nonalcoholic steatohepatitis (NASH) drug failed a third midphase trial, Conatus Pharma was in trouble. It unveiled a plan to lay off 40% of its staffers and find “strategic alternatives” to stay afloat. Now, the company has found its lifeline—a reverse merger with regenerative medicine player Histogen.
Passage Bio is losing its interim chief executive and co-founder Stephen Squinto, Ph.D., as it brings in a venture capitalist veteran to the helm.